Valeant Pharmaceuticals Buy Hold or Sell Recommendation

    VRX -- USA Stock  

    null 18.06  0.78  4.51%

    Considering 30-days investment horizon, and your above average risk tolerance our recommendation regarding Valeant Pharmaceuticals International is 'Not Rated'. Macroaxis provides Valeant Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VRX positions. The advice algorithm takes into account all of Valeant Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from VRX buy-and-hold prospective. Also please take a look at World Market Map.

    Time Horizon

    Risk Tolerance

    Symbol
    Execute Advice
    Sell Valeant PharmaceuticalsBuy Valeant Pharmaceuticals
    Not Rated
    For the selected time horizon Valeant Pharmaceuticals International has a risk adjusted performance of (0.044243), jensen alpha of (0.31), total risk alpha of (1.36), sortino ratio of 0.0 and treynor ratio of 1.05
    Our advice tool can be used to cross verify current analyst consensus on Valeant Pharmaceuticals and to analyze the corporation potential to grow in the current economic cycle. To make sure Valeant Pharmaceuticals is not overpriced, please validate all Valeant Pharmaceuticals fundamentals including its Price to Earning, Net Income, Book Value Per Share, as well as the relationship between Revenue and Total Debt . Given that Valeant Pharmaceuticals has Number of Shares Shorted of 14.62M, we advise you double-check Valeant Pharmaceuticals International market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

    Valeant Pharmaceuticals Trading Alerts and Improvement Suggestions

    Valeant Pharmaceuticals is not yet fully synchronised with the market data
    Valeant Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial commitments
    The company reported last year revenue of 8.61B. Reported Net Loss for the year was (917M) with profit before taxes, overhead, and interest of 6.18B.

    Valeant Pharmaceuticals Returns Distribution Density

    Mean Return0.35Value At Risk6.85
    Potential Upside3.55Standard Deviation4.38
     Return Density 
          Distribution 
    Search macroaxis.com